Revvity Q2 2026: 1% Revenue Growth, $46M Restructuring, and China Immunodiagnostics Divestiture
RVTY sits 42% above its 52-week low of $81.22.
Summary
Revvity posted Q2 2026 revenue of $729.7M (+1% YoY) and GAAP EPS of $0.47. Restructuring charges of $35.5M pressured operating income, and the company announced the divestiture of its China Immunodiagnostics business.
Key Events · Earnings and Guidance · RVTY
-
Q2 Revenue Up 1%, EPS $0.47
Revenue reached $729.7M, driven by 5% growth in Diagnostics, offsetting a 2% decline in Life Sciences. GAAP diluted EPS was $0.47, down from $0.46 a year ago.
-
Restructuring Charges Surge to $35.5M
Restructuring and other costs hit $35.5M in Q2, up from $11.2M last year, as the company cut ~5% of its workforce and consolidated facilities to streamline operations.
-
Tariff Refunds Boost Gross Margin
The company recorded $16.2M in tariff refunds in cost of revenue, helping gross margin expand 260 bps to 57.1%.
-
Divestiture of China Immunodiagnostics
Subsequent to quarter-end, Revvity agreed to sell its China Immunodiagnostics business, which accounted for ~6% of FY2025 revenue. The deal is expected to close by end of 2027.
Analysis · RVTY · Industrial Applications And Services
Revvity's Q2 2026 results delivered a modest 1% revenue increase to $729.7M, but operating income fell as restructuring charges jumped to $35.5M for the quarter. The company is streamlining operations by cutting approximately 5% of its workforce, while $16.2M in tariff refunds provided a lift to gross margins. A subsequent agreement to divest the China Immunodiagnostics business—representing 6% of FY2025 revenue—signals a strategic pivot. The balance sheet remains solid with $1.0B in cash and a $1.5B undrawn credit facility, yet the restructuring and divestiture underscore a shift in focus toward profitability over growth.
At the time of this filing, RVTY was trading at $115.73 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.9B. The 52-week trading range was $81.22 to $118.30. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.